Blueprint Medicines Corp is a pioneer in developing targeted therapies for cancer and blood disorders. With a focus on precision medicine, they are advancing a pipeline of innovative treatments, including AYVAKIT for systemic mastocytosis and gastrointestinal tumors, and GAVRETO for certain types of lung and thyroid cancers. Their research also extends to tackling lung cancer with novel inhibitors and addressing rare conditions like fibrodysplasia ossificans progressive. Based in Cambridge, Massachusetts, Blueprint Medicines is committed to transforming patient outcomes through groundbreaking science.
Tuesday's top analyst upgrades and downgrades included Aflac, Cloudflare, Comerica, Comstock Resources, Costco Wholesale, Dollar General, Dominion Energy, Equitrans Midstream, Ford, Meta Platforms, T-Mobile, Valley National Bancorp and Walmart.
Tuesday’s top analyst upgrades and downgrades included Boeing, Boston Scientific, ChargePoint, Deere, Foot Locker, Horizon Therapeutics, Nu, Ross Stores, Salesforce, United Parcel Service, VF, Vipshop and Walmart.
Wells Fargo issues a few calls and warns investors that these stocks could underperform the markets, even considering the bear market we are in now.
Monday's top analyst upgrades and downgrades included Docusign, Electronic Arts, Enterprise Products Partners, GoodRx, Netflix, Spirit Airlines, Take-Two Interactive Software, Target, Tesla and Vonage.
Wednesday’s additional top analyst upgrades and downgrades were on Danaher, eBay, GoodRx, Infosys, Valero Energy, Xylem and more.
Thursday afternoon's top analyst upgrades and downgrades included Autodesk, Check Point Software, DoorDash, Hilton, Nvidia, Upstart and more.
Wednesday's top analyst upgrades and downgrades included Apple, Applied Materials, BP, Bumble, Carrier, Harley-Davidson, Hess, Illumina, Johnson Controls and Lennar.
Monday's top analyst upgrades and downgrades included AbbVie, Alibaba, Archer Daniels Midland, Best Buy, Intel, Nikola, Peloton Interactive, SAP, Under Armour and Wynn Resorts.
Blueprint Medicines announced early on Tuesday that it had entered into a global collaboration with pharmaceutical giant Roche in which it may receive up to $1.7 billion.
Chris Lange Tuesday's top analyst calls included Advanced Micro Devices, Alcoa, Biomarin Pharmaceutical, Coca-Cola, Ford, General Motors, Intel, Kinder Morgan, Micron Technology, Nvidia, Tesla, Twitter and Zillow.
